CHHIPS (Controlling Hypertension and Hypotension Immediately Post-Stroke) Pilot Trial: Rationale and design

Journal of Hypertension

Volumn 23, Issue 3, 2005, Pages 649-655

  Potter, J F ^a  

^a GLENFIELD HOSPITAL   (United Kingdom)

Author keywords

Antihypertensive treatment; Hypertension; Hypotension; Pressor treatment; Stroke

Indexed keywords

ANTIHYPERTENSIVE AGENT; HYPERTENSIVE AGENT; LABETALOL; LISINOPRIL; PHENYLEPHRINE; PLACEBO;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEATH; DOUBLE BLIND PROCEDURE; DYSPHAGIA; FOLLOW UP; GENERAL HOSPITAL; GOOD CLINICAL PRACTICE; HUMAN; HYPERTENSION; HYPOTENSION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEUROIMAGING; NEUROLOGICAL COMPLICATION; PILOT STUDY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; STATISTICAL ANALYSIS; STROKE; TEACHING HOSPITAL; UNITED KINGDOM;

EID: 18844443146     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000160224.94220.e7     Document Type: Article

References (39)

1. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke. Lancet 1997; 349:1569-1581.
2. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomized placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic stroke. Lancet 1997; 349:1641-1649.
3. Makatas F, Waechter R, Ebis G. Relation between cerebral perfusion pressure and arterial pressure in cerebral edema. Lancet 1972; 1:684.
4. Willmot M, Leonardi-Bee J, Bath PM. High blood pressure in acute stroke and subsequent outcome: a systematic review. Hypertension 2004; 43:18-24.
5. Hoedt-Rasmussen K, Skinhoj E, Paulson O, Ewald J, Bjerrum JK, Fahrenkrug A, et al. Regional cerebral blood flow in acute apoplexy. The luxury perfusion syndrome of brain tissue. Arch Neurol 1967; 17:271-281.
6. Lassen NA. The luxury-perfusion syndrome and its possible relation to acute metabolic acidosis localised within the brain. Lancet 1966; 2:1113-1115.
7. Fieschi C, Agnoli A, Battistini N, Bozzao L, Prencipe M. Derangement of regional blood flow and its regulatory mechanisms in acute cerebrovascular lesions. Neurology 1968; 18:1166-1179.
8. Garcia JH. Relevance of experimental models to clinical stroke. In: Weinstein PR, Fadden AI (editors): Protection of the brain from ischaemia. Baltimore: Maryland: Williams and Wilkins; 1990, pp. 75-79.
9. Robinson TG, Potter JF. Blood pressure in acute stroke. Age Ageing 2004; 33:6-12.
10. Leonardi-Bee J, Bath PMW, Phillips SJ, Sandercock PAG. Blood pressure and clinical outcomes in the International Stroke Trial. Stroke 2002; 33:1315-1320.
11. Robinson T, Ward-Close S, Potter J. A comparison of beat-to-beat blood pressure variability in acute and subacute stroke patients with cerebral infarction. Cerebrovasc Dis 1997; 7:214-219.
12. Robinson TG, Waddington A, Ward-Close S, Taub N, Potter JF. The predictive role of 24-hour compared to casual blood pressure levels on outcome following acute stroke. Cerebrovasc Dis 1997; 7:264-272.
13. Lindley RI, Amayo EO, Marshall J, Sandercock PAG, Dennis M, Warlow CP. Acute stroke treatment in UK hospitals: the Stroke Association survey of consultant opinion. J R Coll Physicians Lond 1995; 29:479-484.
14. Lindenauer PK, Mathew MC, Ntuli TS, Pekow PS, Fitzgerald J, Benjamin EM. Use of antihypertensive agents in the management of patients with acute ischemic stroke. Neurology 2004; 63:318-323.
15. Bhalla A, Wolfe C, Rudd A. Management of blood pressure after acute stroke: a European perspective. Age Ageing 2001; 30:178-179.
16. Blood pressure in Acute Stroke Collaboration (BASC). Interventions for deliberately altering blood pressure in acute stroke (Cochrane Review). The Cochrane Library, Issue 3. Chichester, UK: John Wiley & Sons; 2004.
17. Barer DH, Cruickshank JM, Ebrahim SB, Mitchell JRA. Low dose β blockade in acute stroke ('BEST' trial): an evaluation. BMJ 1988; 296:737-741.
18. Horn J, Limburg M. Calcium antagonists for ischemic stroke: a systematic review. Stroke 2001; 32:570-576.
19. Eames P, Panerai R, Potter J, Robinson T. Bendrofluazide does not reduce arterial blood pressure in the acute stroke period. Cerebrovasc Dis (in press).
20. Bath PMW, Pathansali R, Iddenden R, Bath FJ. The effect of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure and platelet function in acute stroke. Cerebrovasc Dis 2004; 11:265-272.
21. Butterworth RJ, Cluckie A, Jackson SHD, Buxton-Thomas M, Bath PMW. Pathophysiological assessment of nitric oxide (given as sodium nitroprusside) in acute ischaemic stroke. Cerebrovasc Dis 1998; 8:158-165.
22. Lisk DR, Grotta JC, Lamki LM, Tran HD, Taylor JO, Molony DA, et al. Should hypertension be treated after acute stroke? A randomized controlled trial using single photon emission computed tomography. Arch Neurol 1993; 50:855-862.
23. Dyker AG, Grosset DG, Lees K. Perindopril reduces blood pressure but not cerebral blood flow in patients with recent cerebral ischemic stroke. Stroke 1997; 28:580-583.
24. Walters MR, Dyker AG, Lees KR. The effect of perindopril on cerebral and renal perfusion in stroke patients with carotid disease. Cerebrovasc Dis 2000; 10:75.
25. Schrader J, Luders S, Kulschewski A, Berger J, Zidek W, Treib J, et al. The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 2003; 34:1699-1703.
26. Moriwaki H, Uno H, Nagakane Y, Miyashita K, Naritomi H. Losartan, an angiotensin II (AT1) receptor antagonist, preserves cerebral blood flow in hypertensive patients with a history of stroke. J Hum Hypertens 2004; 18:693-699.
27. Patel RV, Kertland HR, Jahns BE, Zarowitz BJ, Mlynarek ME, Fagan SC. Labetolol: response and safety in critically ill hemorrhagic stroke patients. Ann Pharmacother 1993; 27:180-181.
28. Brott T, Lu M, Kothari R, Fagan SC, Frankel M, Grotta JC, et al. Hypertension and its treatment in the NINDS rt-PA stroke trial. Stroke 1998; 29:1504-1509.
29. Tranmer B, Gross C, Keller T, Kindt G. Acute middle cerebral artery occlusion: experience with volume expansion therapy. Neurosurgery 1986; 18:397-401.
30. Duke B, Breeze R, Rubenstein D, Tranmer B, Kindt G. Induced hypervolemia and inotropic support for acute cerebral arterial insufficiency: an underused therapy. Surg Neurol 1998; 49:51-57.
31. Rordorf G, Koroshetz W, Ezzeddine M, Segal A, Buonanno F. A pilot study of drug-induced hypertension for treatment of acute stroke. Neurology 2001; 56:1210-1213.
32. Schwarz S, Georgiadis D, Aschoff A, Schwab S. Effects of induced hypertension on intracranial pressure and flow velocities of the middle cerebral arteries in patients with large hemispheric stroke. Stroke 2002; 33:998-1004.
33. Ramsey DJC, Smithard DG, Kalra L. Early assessments of dysphagia and aspiration risk in acute stroke patients. Stroke 2003; 34:1252-1257.
34. COSSACS Trial Group. COSSACS (Continue Or Stop post-Stroke Anti-hypertensives Collaborative Study): Rationale and Design. J Hypertens (in press).
35. Wityk R, Pessin M, Kaplan R, Caplan L. Assessment of acute stroke using the NIH stroke scale. Stroke 1994; 25:362-365.
36. Rankin J. Cerebral vascular accidents in patients over the age of 60, II: prognosis. Scott Med J 1957; 2:200-215.
37. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991; 337:1521-1526.
38. Mahoney FI, Barthel DW. Functional evaluation: Barthel Index. Md State Med J 1965; 14:61-65.
39. Lepage L, Altman DG, Schultz KF, Moher D, Egger M, Davidoff F, et al., for the CONSORT Group. The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration. Ann Int Med 2001; 134:663-694.